Rytelo (Imetelstat Sodium) Patent Expiration, LOE Window & CMS Spending

Rytelo (Imetelstat Sodium) by Geron: FDA Orange Book core substance LOE 2026-12-27 (last listed 2039-06-16), 0 AB generics, $1.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGeron
FDA Application & PathwayN217779 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2026-12-27
Last Listed Patent or Exclusivity Date2039-06-16
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.7M
2024 Medicare Part D Spend$1.7M
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel